Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
2.
Antivir Ther ; 18(6): 745-54, 2013.
Article in English | MEDLINE | ID: mdl-23558061

ABSTRACT

BACKGROUND: To investigate pharmacokinetic interactions associated with coadministration of lersivirine with zidovudine, tenofovir disoproxil fumarate (DF)/emtricitabine (Truvada(®)) or abacavir/lamivudine (Epzicom(®)/Kivexa(®)). METHODS: Three Phase I, open, crossover studies with two (studies 1 and 3) or three (study 2) treatment periods were conducted in healthy individuals. In study 1, individuals received zidovudine and placebo or zidovudine and lersivirine on days 1-14. In study 2, individuals received lersivirine and tenofovir DF/emtricitabine, lersivirine and placebo or tenofovir DF/emtricitabine and placebo on days 1-10. In study 3, individuals received abacavir/lamivudine only in period 1 (5 days) and abacavir/lamivudine and lersivirine in period 2 (10 days). Blood samples were taken on days 1-14 (study 1) or day of final dose (studies 2 and 3) and analysed using high performance liquid chromatography/dual mass spectrometry. Pharmacokinetic parameters were calculated by standard non-compartmental methods. RESULTS: When coadministered with lersivirine, zidovudine exposure increased by 35%, and exposure of its metabolite zidovudine-glucuronide decreased by 19%. Following coadministration of lersivirine and tenofovir DF/emtricitabine, tenofovir exposure increased by 30%, and lersivirine exposure decreased by 12%. Coadministration of lersivirine and abacavir/lamivudine increased abacavir exposure by 27% and decreased lamivudine exposure by 8%. Adverse events were predominantly mild in these Phase I studies. CONCLUSIONS: Coadministration of lersivirine with zidovudine, tenofovir DF/emtricitabine or abacavir/lamivudine influenced the systemic exposure of all nucleoside reverse transcriptase inhibitor agents investigated (except for lamivudine; emtricitabine pharmacokinetics were not assessed). Changes were not considered clinically meaningful for zidovudine and abacavir. The clinical relevance of the effect on tenofovir pharmacokinetics is currently unknown.


Subject(s)
Adenine/analogs & derivatives , Anti-HIV Agents/pharmacokinetics , Deoxycytidine/analogs & derivatives , Dideoxynucleosides/pharmacokinetics , Lamivudine/pharmacokinetics , Nitriles/pharmacokinetics , Organophosphonates/pharmacokinetics , Pyrazoles/pharmacokinetics , Zidovudine/pharmacokinetics , Adenine/administration & dosage , Adenine/adverse effects , Adenine/pharmacokinetics , Adult , Anti-HIV Agents/administration & dosage , Anti-HIV Agents/adverse effects , Deoxycytidine/administration & dosage , Deoxycytidine/adverse effects , Deoxycytidine/pharmacokinetics , Dideoxynucleosides/administration & dosage , Dideoxynucleosides/adverse effects , Drug Combinations , Drug Interactions , Emtricitabine , Female , HIV Infections/drug therapy , HIV Infections/virology , Healthy Volunteers , Humans , Lamivudine/administration & dosage , Lamivudine/adverse effects , Male , Middle Aged , Nitriles/administration & dosage , Nitriles/adverse effects , Organophosphonates/administration & dosage , Organophosphonates/adverse effects , Pyrazoles/administration & dosage , Pyrazoles/adverse effects , Tenofovir , Young Adult , Zidovudine/administration & dosage , Zidovudine/adverse effects
3.
Antimicrob Agents Chemother ; 56(8): 4303-9, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22644026

ABSTRACT

Lersivirine is a nonnucleoside reverse transcriptase inhibitor (NNRTI) with a unique resistance profile exhibiting potent antiviral activity against wild-type HIV and several clinically relevant NNRTI-resistant strains. Lersivirine, a weak inducer of the cytochrome P450 (CYP) enzyme CYP3A4, is metabolized by CYP3A4 and UDP glucuronosyltransferase 2B7 (UGT2B7). Two open, randomized, two-way (study 1; study A5271008) or three-way (study 2; study A5271043) crossover phase I studies were carried out under steady-state conditions in healthy subjects. Study 1 (n = 17) investigated the effect of oral rifampin on the pharmacokinetics (PKs) of lersivirine. Study 2 (n = 18) investigated the effect of oral rifabutin on the PKs of lersivirine and the effect of lersivirine on the PKs of rifabutin and its active metabolite, 25-O-desacetyl-rifabutin. Coadministration with rifampin decreased the profile of the lersivirine area under the plasma concentration-time curve from time zero to 24 h postdose (AUC(24)), maximum plasma concentration (C(max)), and plasma concentration observed at 24 h postdose (C(24)) by 85% (90% confidence interval [CI], 83, 87), 83% (90% CI, 79, 85), and 92% (90% CI, 89, 94), respectively, versus the values for lersivirine alone. Coadministration with rifabutin decreased the lersivirine AUC(24), C(max), and C(24) by 34% (90% CI, 29, 39), 25% (90% CI, 16, 33), and 58% (90% CI, 52, 64), respectively, compared with the values for lersivirine alone. Neither the rifabutin concentration profile nor overall exposure was affected following coadministration with lersivirine. Lersivirine and rifabutin reduced the 25-O-desacetyl-rifabutin AUC(24) by 27% (90% CI, 21, 32) and C(max) by 27% (90% CI, 19, 34). Lersivirine should not be coadministered with rifampin, which is a potent inducer of CYP3A4, UGT2B7, and P-glycoprotein activity and thus substantially lowers lersivirine exposure. No dose adjustment of rifabutin is necessary in the presence of lersivirine; an upward dose adjustment of lersivirine may be warranted when it is coadministered with rifabutin.


Subject(s)
Nitriles/pharmacology , Nitriles/pharmacokinetics , Pyrazoles/pharmacology , Pyrazoles/pharmacokinetics , Rifabutin/pharmacology , Rifabutin/pharmacokinetics , Rifampin/pharmacology , Adolescent , Adult , Cross-Over Studies , Cytochrome P-450 CYP3A/metabolism , Drug Administration Schedule , Drug Interactions , Drug Therapy, Combination , Female , Glucuronosyltransferase/metabolism , HIV/drug effects , HIV Infections/drug therapy , Humans , Male , Middle Aged , Nitriles/administration & dosage , Nitriles/adverse effects , Pyrazoles/administration & dosage , Pyrazoles/adverse effects , Reverse Transcriptase Inhibitors/administration & dosage , Reverse Transcriptase Inhibitors/pharmacokinetics , Reverse Transcriptase Inhibitors/pharmacology , Rifabutin/administration & dosage , Rifabutin/analogs & derivatives , Rifampin/administration & dosage , Young Adult
4.
J Acquir Immune Defic Syndr ; 60(1): 24-32, 2012 May 01.
Article in English | MEDLINE | ID: mdl-22517413

ABSTRACT

OBJECTIVE: Lersivirine (UK-453,061) is a next-generation nonnucleoside reverse transcriptase inhibitor, active against wild-type HIV-1 and several nonnucleoside reverse transcriptase inhibitor-resistant strains. Four studies evaluated the pharmacokinetic (PK) interactions between lersivirine and various HIV-1 protease inhibitors. METHODS: Four phase I trials were conducted to assess the PK of lersivirine when coadministered with lopinavir/ritonavir, darunavir/ritonavir, or atazanavir with/without ritonavir, and to examine the effects of lersivirine on the PK of atazanavir with/without ritonavir. PK data included the area under the plasma concentration-time profile from time zero to the end of the dosing interval (AUC24), maximum plasma concentration (Cmax), minimum plasma concentration (Cmin, C24, or Ctrough), and time to Cmax (Tmax). Safety was assessed by recording adverse events, vital signs, and laboratory data. RESULTS: Coadministration of lersivirine with lopinavir/ritonavir, darunavir/ritonavir, or atazanavir/ritonavir decreased mean plasma lersivirine AUC24 by 43%, 22%, and 19%, respectively. Atazanavir had no effect on lersivirine exposure, except for a 16% decrease in lersivirine C24. Lersivirine had no effect on atazanavir AUC24 or Cmax, although Ctrough was reduced by 18% in the absence of ritonavir. CONCLUSIONS: Lersivirine exposure was reduced when coadministered with ritonavir-boosted protease inhibitors; a dose adjustment may be warranted. Unboosted atazanavir had no effect on lersivirine exposure, except for a small decrease in lersivirine C24. Lersivirine had no effect on atazanavir (with/without ritonavir) exposure, except for a decrease in Ctrough. Caution should be applied when unboosted atazanavir is coadministered with lersivirine. Coadministration of lersivirine with lopinavir/ritonavir, darunavir/ritonavir, or atazanavir with/without ritonavir seems to be generally well tolerated.


Subject(s)
Anti-HIV Agents/administration & dosage , Anti-HIV Agents/pharmacokinetics , Antiretroviral Therapy, Highly Active/methods , HIV Protease Inhibitors/administration & dosage , HIV Protease Inhibitors/pharmacokinetics , Nitriles/administration & dosage , Nitriles/pharmacokinetics , Pyrazoles/administration & dosage , Pyrazoles/pharmacokinetics , Adult , Anti-HIV Agents/adverse effects , Antiretroviral Therapy, Highly Active/adverse effects , Female , HIV Protease Inhibitors/adverse effects , Humans , Male , Middle Aged , Nitriles/adverse effects , Plasma/chemistry , Pyrazoles/adverse effects
5.
Antimicrob Agents Chemother ; 55(9): 4302-7, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21709083

ABSTRACT

A double-blind, placebo-controlled, four-way crossover study was conducted in 40 subjects to assess the effect of linezolid on corrected QT (QTc) interval prolongation. Time-matched, placebo-corrected QT intervals were determined predose and at 0.5, 1 (end of infusion), 2, 4, 8, 12, and 24 h after intravenous dosing of linezolid 600 and 1,200 mg. Oral moxifloxacin at 400 mg was used as an active control. The pharmacokinetic profile of linezolid was also evaluated. At each time point, the upper bound of the 90% confidence interval (CI) for placebo-corrected QTcF values (i.e., QTc values adjusted for ventricular rate using the correction methods of Fridericia) for linezolid 600 and 1,200-mg doses were <10 ms, which indicates an absence of clinically significant QTc prolongation. At 2 and 4 h after the moxifloxacin dose, corresponding to the population T(max), the lower bound of the two-sided 90% CI for QTcF when comparing moxifloxacin to placebo was >5 ms, indicating that the study was adequately sensitive to assess QTc prolongation. The pharmacokinetic profile of linezolid at 600 mg was consistent with previous observations. Systemic exposure to linezolid increased in a slightly more than dose-proportional manner at supratherapeutic doses, but the degree of nonlinearity was small. At a supratherapeutic single dose of 1,200 mg of linezolid, no treatment-related increase in adverse events was seen compared to 600 mg of linezolid, and no clinically meaningful effects on vital signs and safety laboratory evaluations were noted.


Subject(s)
Acetamides/adverse effects , Anti-Infective Agents/adverse effects , Arrhythmias, Cardiac/chemically induced , Oxazolidinones/adverse effects , Acetamides/therapeutic use , Adult , Aza Compounds/adverse effects , Aza Compounds/therapeutic use , Cross-Over Studies , Double-Blind Method , Drug Administration Schedule , Female , Fluoroquinolones , Gram-Positive Bacterial Infections/drug therapy , Humans , Linezolid , Male , Middle Aged , Moxifloxacin , Oxazolidinones/therapeutic use , Quinolines/adverse effects , Quinolines/therapeutic use , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...